Why BGPT?
logo

Evidence Paper Review

Analyze how experimental results and claims are presented, scoped, and limited in a paper.Know what the science actually supports before you trust the answer.

Press Enter ↵ to analyze



    Explore by Goal












     Quick Explanation


    The Qualia NAD+ trial reports that 28 days of supplementation raised whole blood NAD+ by 74% vs 4% placebo (p<0.001) in 25 adults, but commercial funding, n=9 per-arm imbalance, spot-assay methodology, and absence of objective functional endpoints substantially limit interpretation.


     Long Explanation


    What the Study Reports

    This randomized, double-blind, placebo-controlled trial gave 25 healthy adults aged 40-65 (56% female) Qualia NAD+ (n=9) or placebo (n=16) for 28 days. Whole blood NAD+, measured by self-administered dried blood spot assay, rose from 19.64±3.63 µM to 34.20±5.88 µM in the treatment arm (+14.56±5.79 µM, p<0.001; ~74%), while placebo moved only from 19.06±4.44 to 19.77±4.70 µM (+0.71±3.00 µM, p=0.35) . Quality-of-life questionnaire improvements appeared only in male participants.

    Critical Concerns

    Funding and conflicts of interest. Qualia Life Sciences supplied the product, employed four authors, and was involved in writing, editing, approval, and the decision to publish — a sponsor fully embedded in both data generation and publication, a classic sponsor-bias configuration. Registration (NCT06812416) postdates the March 2025 preprint date, raising timing questions. Design. n=9 treatment vs n=16 placebo is imbalanced and severely underpowered for sex-stratified QoL analyses; positive QoL findings in males (subgroup of a subgroup) are especially vulnerable to multiplicity and HARKing. Measurement. A home dried blood spot assay was not validated against the HPLC/LC-MS methods standard in the NAD literature , and the broader NAD metabolome (NMN, NR, NAM, NaAD) was uncharacterized. Endpoints. Only subjective self-reported outcomes support benefit; no objective functional, metabolic, or tissue-NAD measures were included. Biological context. Mechanistically plausible — salvage-pathway kinetics are well characterized, and precursor-driven NAD elevation is reproducible in cells and mice — but elevated blood NAD+ is a surrogate with unproven clinical meaning.

    Blind Spots and What Would Change the Verdict

    Hidden assumptions: (1) that whole blood NAD+ tracks intracellular/tissue NAD+; (2) that a 74% acute rise is safe long-term; (3) that NAD+ elevation equates to health benefit. The bioenergetics literature warns that more NAD+ is not monotonically better — even in yeast, both too little and too much mitochondrial NAD+ import reduced bioenergetic efficiency . Independent replication with third-party LC-MS verification, balanced arms, preregistered objective endpoints, and independent funding would be needed to overturn the skeptical assessment; conversely, a failed independent replication or adverse long-term data would falsify the paper's promotional framing.



    Feedback:    

    Updated: October 29, 2026



     BGPT Paper Review


    Study Novelty

    50%

    NAD+-boosting supplementation trials are an increasingly crowded, largely industry-driven literature; the 'systems approach' formulation and multi-ingredient blend add marketing novelty rather than scientific novelty.


    Scientific Quality

    50%

    Preprint with placebo control and blinding is commendable, but sponsor employment of four authors, publication-decision control, imbalanced arms (n=9 vs 16), unvalidated home blood-spot assay, subjective-only benefit endpoints, and postdated trial registration all cap scientific quality.


    Study Generality

    40%

    Findings apply narrowly to a proprietary multi-ingredient supplement in 25 healthy middle-aged adults; no mechanistic generality or transferable methodology beyond another precursor-raising-NAD result.


    Study Usefulness

    40%

    Useful mainly as commercial product-support evidence and as a cautionary case study in sponsor-run nutrition trials; limited contribution to NAD biology or translational knowledge.


    Study Reproducibility

    40%

    Protocol and registration number are stated, but the proprietary formulation, non-validated home assay, and no deposited raw data hinder independent replication.


    Explanatory Depth

    40%

    The paper does not identify which of the many blend components drove the NAD+ rise, nor measure intermediate metabolites, leaving mechanism undefined.

     Top Data Sources ExportMCP


     Analysis Wizard



    Building an open NAD+ trial registry comparison, extracting effect sizes and sponsor-status from published NAD-boosting human trials to benchmark this result.



     Hypothesis Graveyard


    'The dried blood spot assay explains the 74% rise as artifact' — unlikely alone, since the placebo arm using the identical assay was stable, arguing against a pure assay artifact.

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending